Swedish Orphan Biovitrum AB (publ) (Sobi) was awarded the EURORDIS Company Award 2014 at the EURORDIS Black Pearl Gala Dinner on February 25. The award recognises pioneering companies developing treatments for rare diseases. Sobi was honoured based on the treatments in the company’s commercial and development portfolio, on the company’s policy and track record on access to drugs, and on its collaboration with patient organisations.
“We are honoured to acknowledge the commitment and achievements of the recipients of the EURORDIS Awards on the occasion of Rare Disease Day 2014. This year, Rare Disease Day puts the spotlight on Care. Each of the 11 EURORDIS Award 2014 recipients is making a significant and unique contribution to improving access to the many different kinds of Care people living with a rare disease need and deserve. Working together, we are starting to make a real difference to the millions of patients and families throughout Europe who live with a rare disease,” said Yann Le Cam, Chief Executive Officer, EURORDIS.
The purpose of the EURORDIS Awards is to recognise the outstanding commitment and achievements of patients’ organisations, volunteers, companies, scientists, media and policy makers who have contributed to reducing the impact of rare diseases on people’s lives.
“We are proud to be honoured by EURORDIS.” said Geoffrey McDonough, Chief Executive Officer, Sobi. “We are inspired to pioneer a world in which rare disease patients are diagnosed at birth,receive effective and sustainable therapy, and go on to live full and healthy lives. Collaboration with leading patients’ organizations such as EURORDIS is fundamental to this work.”
EURORDIS is a leading International Non-Governmental Organisation (INGO) and is recognised as the largest European Patient Organisation in the field of rare diseases. EURORDIS represents more than 614 rare disease organisations in 58 different countries, covering more than 4,000 distinct rare diseases. EURORDIS is the voice of an estimated 30 million patients affected by rare diseases throughout Europe.
For more information please contact
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflamma-tion and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More infor-mation is available at www.sobi.com.